natgillin/translations-raw huggingface dataset:
In individual cases where the benefit of administering ribavirin concomitantly with azathioprine warrants the potential risk, it is recommended that close hematologic monitoring be done during concomitant azathioprine use to identify signs of myelotoxicity, at which time treatment with these medicines should be stopped (see section 4.4).
V posameznih primerih, kjer je korist sočasnega zdravljenja z ribavirinom in azatioprinom večja kot možno tveganje, je med sočasnim zdravljenjem z azatioprinom priporočljivo skrbno spremljanje hematoloških parametrov, da se lahko ugotovijo znaki mielotoksičnosti.
thoughts about threatening the life of others, mania (excessive or unreasonable enthusiasm), pericarditis (inflammation of the lining of the heart), pericardial effusion [a fluid collection that develops between the pericardium (the lining of the heart) and the heart itself], change in colour of the tongue.
- misli kako ogroziti življenja drugih, - manija (pretirano in nerazumno navdušenje), - perikarditis (vnetje srčne zaklopke), perikardno iztekanje tekočina se nabira med perikardom
When used in combination with peginterferon alfa-2b or interferon alfa-2b, ribavirin did not cause any effects not previously seen with either active substance alone.
Ribavirin v kombinaciji s peginterferonom alfa-2b ali interferonom alfa-2b ni povzročil nobenih učinkov, ki ne bi že bili opisani v zvezi s samostojno uporabo obeh učinkovin.
A reduction in haemoglobin concentrations by > 4 g/dL was observed in 30 % of patients treated with ribavirin and peginterferon alfa-2b and 37 % of patients treated with ribavirin and interferon alfa-2b.
Znižanje koncentracije hemoglobina za > 4 g/dl so opazili pri 30 % bolnikov, ki so prejemali ribavirin in peginterferon alfa-2b, ter pri 37 % bolnikov, ki so prejemali ribavirin in interferon alfa-2b.
Hypothyroidism, hyperthyroidism
hipotiroidizem, hipertiroidizem
Reminder: This medicine is only to be used in combination with other medicines for hepatitis C virus infection.
Opozorilo: To zdravilo se lahko uporablja samo v kombinaciji z drugimi zdravili za zdravljenje virusne okužbe s hepatitisom C. Za popolnejše informacije morate prebrati tudi poglavje
However, ribavirin systemic exposure of a female partner after sexual intercourse with a treated patient has been estimated and remains extremely limited compared to therapeutic plasma concentration of ribavirin.
Koncentracija ribavirina v semenski tekočini je približno dvakrat večja kot v serumu, vendar ko so ocenili sistemsko izpostavljenost ribavirinu pri partnerki po spolnem odnosu z zdravljenim bolnikom, je bila ta še vedno zelo majhna v primerjavi s terapevtskimi plazemskimi koncentracijami ribavirina.
Light pink to pink, (debossed with “93” on one side and “7232” on the other).
filmsko obložena tableta Svetlo rožnate do rožnate tablete (z vtisnjenim »93« na eni strani in »7232« na drugi strani).
Ribavirin concentrations are essentially unchanged by haemodialysis.
Hemodializa praktično ne spremeni koncentracije ribavirina.
If you take more Ribavirin Teva Pharma B.V. than you should
Če ste vzeli večji odmerek zdravila Ribavirin Teva Pharma B.V., kot bi smeli
The exacerbation of anaemia due to ribavirin has been reported when zidovudine is part of the regimen used to treat HIV although the exact mechanism remains to be elucidated.
Kadar je bil zidovudin vključen v shemo zdravljenja okužbe s HIV, so poročali o poslabšanju anemije zaradi uporabe ribavirina, čeprav natančen mehanizem tega pojava ni znan.
Reminder: Please read the “Other medicines” section of the Package Leaflet for the other medicines used in combination with Ribavirin Teva Pharma B.V. before you begin combination treatment with this medicine.
Opozorilo: Prosimo, preberite tudi poglavje “Druga zdravila” v navodilih za druga zdravila, uporabljena v kombinaciji z zdravilom Ribavirin Teva Pharma B.V., preden začnete s kombiniranim zdravljenjem s tem zdravilom.
During combination therapy for up to 48 weeks with interferon alfa2b and ribavirin, growth inhibition was observed that resulted in reduced final adult height in some patients.
V času kombinirane terapije z interferonom alfa-2b in ribavirinom, ki je trajala do 48 tednov, so opazili zastoj rasti, ki je pri nekaterih bolnikih povzročil manjšo končno telesno višino v odrasli dobi.
Note: For patients who weigh < 47 kg, or are unable to swallow tablets, ribavirin oral solution is available and should be used if appropriate.
Opomba: Za bolnike, ki tehtajo < 47 kg ali ne morejo pogoltniti tablete, je na voljo peroralna raztopina ribavirina.
In addition, injection site disorders, pyrexia, anorexia, vomiting, and emotional lability occurred more frequently in children and adolescents compared to adult patients.
Poleg tega so se pri otrocih in mladostnikih pogosteje kot pri odraslih bolnikih pojavile težave na mestu injiciranja, pireksija, anoreksija, bruhanje in čustvena labilnost.
In the HIV-positive population receiving an NRTI regimen, physicians should carefully monitor markers of mitochondrial toxicity and lactic acidosis when ribavirin is administered.
Pri bolnikih, pozitivnih na HIV, ki se zdravijo po shemi NRTI, mora zdravnik pri sočasnem zdravljenju z ribavirinom skrbno spremljati pokazatelje mitohondrijske toksičnosti in laktacidoze.
Table 5 Adverse reactions reported during clinical trials or following the marketing use of ribavirin with pegylated interferon alfa-2b or interferon alfa-2b
Preglednica 5 Neželeni učinki, o katerih so poročali med kliničnimi preskušanji ali v obdobju trženja z uporabo ribavirina skupaj s pegiliranim interferonom alfa-2b ali interferonom alfa-2b
Tabulated list of adverse reactions in paediatric population Reported adverse reactions listed in Table 6 are based on experience from the two multicentre children and adolescents clinical trials using ribavirin with interferon alfa-2b or peginterferon alfa-2b.
Seznam neželenih učinkov pri pediatrični populaciji v preglednici Neželeni učinki, o katerih so poročali in so navedeni v preglednici 6, temeljijo na izkušnjah iz dveh multicentričnih študij pri otrocih in mladostnikih, kjer so uporabljali ribavirin z interferonom alfa-2b ali peginterferonom alfa-2b.
Chest pain, oedema, pain, feeling cold
bolečine v prsih, edem, bolečine, občutek mraza
Myocardial infarction
miokardni infarkt
The sustained response at the end of follow-up was significantly increased by the addition of ribavirin to interferon alfa-2b (41 % vs 16 %, p < 0.001).
Trajni odziv na koncu spremljanja bolnikov je bil bistveno večji (41 % proti 16 %, p < 0,001) zaradi dodatka ribavirina interferonu alfa-2b.
- Breast-feeding - History of severe pre-existing cardiac disease, including unstable or uncontrolled cardiac disease, in the previous six months (see section 4.4).
ne smete uvesti, dokler ne dobite negativnega izvida testa nosečnosti tik pred začetkom zdravljenja - Dojenje - Huda obstoječa srčna bolezen v anamnezi, vključno z nestabilno ali nenadzorovano srčno boleznijo v preteklih šestih mesecih (glejte poglavje 4.4) - Hemoglobinopatije (npr. talasemija, anemija srpastih celic)
Co-administration of ribavirin and didanosine is not recommended.
Sočasna uporaba ribavirina in didanozina ni priporočljiva.
Haematological abnormalities were more frequently reported in patients receiving ribavirin in combination with peginterferon alfa-2b when compared to patients receiving ribavirin in combination with interferon alfa-2b.
O hematoloških motnjah so poročali pogosteje pri bolnikih, ki so prejemali ribavirin v kombinaciji s peginterferonom alfa-2b, kot pri tistih, ki so prejemali ribavirin v kombinaciji z interferonom alfa-2b.
Ribavirin (1,000/1,200 mg) + interferon alfa-2b (3 MIU)
ribavirin (1.000/1.200 mg) + interferon alfa-2b (3 mio)
The adverse reactions listed in this section are primarily derived from clinical trials and/or as adverse drug reactions from spontaneous reports when ribavirin was used in combination with interferon alfa-2b or peginterferon alfa-2b.
Neželeni učinki, navedeni v tem poglavju, izvirajo v prvi vrsti iz kliničnih preskušanj in/ali spontano poročanih neželenih učinkov, ko je bil ribovirin uporabljeno v kombinaciji z interferonom alfa-2b ali peginterferonom alfa-2b.
While changes in laboratory values were observed in some patients treated with ribavirin used in combination with peginterferon alfa-2b in the clinical trial, values returned to baseline levels within a few weeks after the end of therapy.
Čeprav so v kliničnem preskušanju pri nekaterih bolnikih, ki so prejemali ribavirin v kombinaciji s peginterferonom alfa-2b, opazili spremembe laboratorijskih vrednosti, pa so se le-te povrnile na začetne vrednosti že v nekaj tednih po koncu zdravljenja.
HCV/HIV co-infected patients receiving peginterferon alfa-2b/ribavirin treatment and cART may be at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia and anaemia) compared to HCV mono-infected patients.
Bolniki, ki so sočasno okuženi z virusom HCV in HIV ter se zdravijo s peginterferonom alfa2b/ribavirinom in s terapijo cART, imajo lahko zvečano tveganje za nastanek hematoloških motenj (v obliki nevtropenije, trombocitopenije in anemije) v primerjavi s tistimi, ki so okuženi samo s HCV.
Hyperkinesia, tremor, dysphonia, paresthaesia, hypoaesthesia, hyperaesthesia, concentration impaired, somnolence, disturbance in attention, poor quality of sleep
hiperkinezija, tremor, disfonija, parestezije, hipoestezija, hiperestezija, motnje koncentracije, somnolenca, motnje pozornosti, slaba kakovost spanja
is indicated, in a combination regimen with interferon alfa-2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for serum HCV-RNA.
je indicirano za kombinirano terapijo z interferonom alfa-2b za zdravljenje otrok, starih 3 leta ali več, ki imajo vse tipe predhodno nezdravljenega kroničnega hepatitisa C, razen genotipa 1, brez jetrne dekompenzacije in pozitiven izvid na RNA-HCV.
6.6 Special precautions for disposal
6.6 Posebni varnostni ukrepi za shranjevanje
Ribavirin Teva Pharma B.V. is available in different pack sizes containing 14, 28, 42, 56, 84, 112, 140 or 168 tablets.
je na voljo v različnih velikostih pakiranj, ki vsebujejo 14, 28, 42, 56, 84, 112, 140 ali 168 tablet.
Contact your doctor immediately if you notice any of the following side effects occuring during combination treatment with other medicines: - chest pain or persistent cough; changes in the way your heart beats; fainting, - confusion, feeling depressed; suicidal thoughts or aggressive behaviour, attempt suicide, thoughts about threatening the life of others, - feelings of numbness or tingling, - trouble sleeping, thinking or concentrating, - severe stomach pain; black or tar-like stools; blood in stool or urine; lower back or side pain, - painful or difficult urination, - severe bleeding from your nose, - fever or chills beginning after a few weeks of treatment, - problems with your eyesight or hearing, - severe skin rash or redness.
Nemudoma se posvetujte s svojim zdravnikom, če opazite katerega koli od naslednjih neželenih učinkov med zdravljenjem v kombinaciji z drugimi zdravili: - bolečine v prsih ali trdovraten kašelj; spremembe srčnega utripa; omedlevica; - zmedenost, depresivnost; samomorilne misli ali agresivno vedenje, poskus samomora; misli kako ogroziti življenja drugih; - občutek odrevenelosti ali mravljincev; - težave s spanjem, razmišljanjem ali zbranostjo; - hude bolečine v želodcu; črno ali smolnato blato; kri v blatu ali urinu; bolečine v spodnjem delu hrbta ali ob strani; - hude krvavitve iz nosu; - zvišana telesna temperatura ali mrzlica, ki nastopi nekaj tednov po začetku zdravljenja; - težave z vidom ali sluhom; - hud kožni izpuščaj ali pordelost.
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND
D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO
Alopecia, rash
alopecija, izpuščaj
Ribavirin Dose (daily)
Odmerek ribavirina (dnevni)
• Ribavirin (1,000/1,200 mg/day) + interferon alfa-2b (3 MIU three times a week) (n = 505).
 ribavirin (1.000/1.200 mg/dan) + interferon alfa-2b (3 mio i.e. trikrat na teden) (n = 505).
Cardiomyopathy*, arrhythmia*
kardiomiopatija*, aritmije*
Reminder: Please read the “Do not take” section of the Package leaflet for the other medicines used in combination before you begin combination treatment with this medicine.
Opozorilo: Preberite tudi poglavje “Ne jemljite” v navodilih za druga zdravila, uporabljena v kombinaciji s tem zdravilom.
Face oedema
obrazni edem
Please refer to the corresponding SmPC of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with ribavirin.
Prosimo, glejte ustrezne povzetke glavnih značilnosti protiretrovirusnih zdravil, uporabljenih sočasno s terapijo za HCV, da bi se bolj zavedali in bi lahko obvladovali toksične učinke vsakega od teh zdravil ter potencialno prekrivanje njihovih toksičnih učinkov z ribavirinom.
Erythrocytes are a primary target of toxicity for ribavirin in animal studies.
V študijah na živalih je ribavirin toksičen predvsem za eritrocite.
Adult patients with severe renal impairment (creatinine clearance of < 30 mL/minute) and patients with End Stage Renal Disease (ESRD) or on haemodialysis should be administered ribavirin 200 mg/day.
Odrasli bolniki s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) in bolniki s končno odpovedjo ledvic (ESRD - end stage renal disease) ali tisti na hemodializi morajo prejemati 200 mg ribavirina na dan. Preglednica 4 prikazuje smernice za prilagoditev odmerka pri bolnikih z motnjami delovanja ledvic.
Ribavirin Teva Pharma B.V. 200 mg film-coated tablets are light-pink to pink, (debossed with “93” on one side and “7232” on the other).
200 mg filmsko obložene tablete so svetlo rožnate do rožnate (z vtisnjenim »93« na eni strani in »7232« na drugi strani).
If you are a HCV/HIV co-infected adult patient receiving anti-HIV treatment, the addition of this medicine and peginterferon alfa-2b may increase your risk of worsening liver function combined antiretroviral therapy (cART) and increase your risk of lactic acidosis, liver failure, and blood abnormalities development (reduction in number of red blood cells which carry oxygen, certain white blood cells that fight infection, and blood clotting cells called platelets) (NRTI).
Če ste odrasel bolnik, ki je sočasno okužen z virusoma HCV in HIV in prejema terapijo proti virusu HIV, lahko dodatek tega zdravila in peginterferona alfa-2b k terapiji poveča tveganje za motnje delovanja jeter, kombinirana protiretrovirusna terapija (cART) in tudi tveganje za nastanek laktacidoze, jetrne odpovedi in krvnih motenj (npr. zmanjšanje števila rdečih krvničk, ki prenašajo kisik po telesu, zmanjšanje števila določenih belih krvničk, ki služijo za boj proti okužbam, in zmanjšanje števila krvničk, ki so odgovorne za strjevanje krvi in jim pravimo trombociti) (NRTI).
• Dental and periodontal disorders: Dental and gum disorders have been reported in patients receiving ribavirin in combination with (peg)interferon alfa-2b.
• Zobne in obzobne bolezni: Pri bolnikih, ki so prejemali ribavirin v kombinaciji s (peg)interferonom alfa-2b, so poročali o boleznih zob in dlesni.
Mitochondrial toxicity and lactic acidosis: Caution should be taken in HIV-positive subjects coinfected with HCV who receive nucleoside reverse transcriptase inhibitor (NRTI) treatment (especially ddI and d4T) and associated interferon alfa-2b/ribavirin treatment.
Mitohondrijska toksičnost in laktacidoza: Pri bolnikih s pozitivnim izvidom na HIV in sočasno okužbo s HCV, ki se zdravijo z nukleozidnim zaviralcem reverzne transkriptaze (NRTI - nucleoside reverse transcriptase inhibitor) (posebno ddI in d4%) v povezavi z interferonom alfa in ribavirinom, je potrebna previdnost.
Only 1 subject discontinued therapy as the result of an adverse reaction (thrombocytopenia).
Zaradi neželenih učinkov je bilo zdravljenje ukinjeno le pri enem preiskovancu (po pojavu trombocitopenije).
Ribavirin Teva Pharma B.V. 400 mg film-coated tablets are light-pink to pink, (debossed with “R” on one side and “400” on the other).
400 mg filmsko obložene tablete so svetlo rožnate do rožnate (z vtisnjenim »R« na eni strani in »400« na drugi strani).
Hepatic decompensation in HCV/HIV co-infected patients with advanced cirrhosis:
Jetrna dekompenzacija pri bolnikih, ki so sočasno okuženi s HCV in HIV in imajo napredovalo cirozo jeter:
Ribavirin, by having an inhibitory effect on inosine monophosphate dehydrogenase, may interfere with azathioprine metabolism possibly leading to an accumulation of 6-methylthioinosine monophosphate (6-MTIMP), which has been associated with myelotoxicity in patients treated with azathioprine.
Zaradi inhibitornega učinka na inozin-monofosfat-dehidrogenazo lahko ribavirin vpliva na presnovo azatioprina, kar lahko privede do kopičenja 6-metiltioinozin monofosfata (6-MTIMP).
Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, Section 4.2)
Predpisovanje in izdaja zdravila je le na recept s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
This medicine in combination with an alpha interferon product may also cause: aplastic anaemia, pure red cell aplasia (a condition where the body stopped or reduced the production of red blood cells); this causes severe anaemia, symptoms of which would include unusual tiredness and a lack of energy,
To zdravilo v kombinaciji z zdravilom z interferonom alfa povzroči tudi: - aplastično anemijo, aplazijo rdečih krvnih celic (stanje, pri katerem telo preneha izdelovati rdeče krvne celice oziroma se njihovo nastajanje zmanjša).
Patients whose dose of Ribavirin Teva Pharma B.V. is reduced to 600 mg daily receive one 200 mg tablet in the morning and two 200 mg tablets in the evening.
je zmanjšan na 600 mg na dan, naj prejmejo po eno 200 mg tableto zjutraj in dve 200 mg tableti zvečer.
Table 6 Adverse reactions very commonly, commonly and uncommonly reported during clinical trials in children and adolescents with ribavirin in combination with interferon alfa-2b or peginterferon alfa-2b
Preglednica 6 Neželeni učinki, o katerih so zelo pogosto, pogosto ali občasno poročali med kliničnimi preskušanji pri otrocih in mladostnikih z ribavirinom v kombinaciji z interferonom alfa-2b ali peginterferonom alfa-2b.
Each film-coated tablet contains 200 mg of ribavirin.
Ena filmsko obložena tableta vsebuje 200 mg ribavirina.
2 tablets in the morning and 2 tablets in the evening See adult dose
2 tableti zjutraj in 2 tableti zvečer
Chest pain, chest discomfort, peripheral oedema, malaise, feeling abnormal, thirst
bolečine v prsih, tiščanje v prsih, periferni edem, splošno slabo počutje, nenormalno počutje, žeja
Ribavirin Teva Pharma B.V. is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, children 3-years of age or older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b.
je indicirano za zdravljenje kroničnega hepatitisa C (HCV) pri odraslih, otrocih starejših od 3 let in mladostnikih in ga morate uporabljati izključno v kombinaciji z interferonom alfa-2b.
The combination of Ribavirin Teva Pharma B.V. with interferon alfa-2b is used to treat patients 3 years of age and older who have chronic hepatitis C (HCV) infection.
je namenjeno uporabi z interferonom alfa-2b za zdravljenje otrok starih 3 leta in več, ki imajo kronični hepatitis C (HCV).
Please read the “Possible side effects” section of the Package Leaflet for the other medicines used in combination with Ribavirin Teva Pharma B.V..
Preberite poglavje »Možni neželeni učinki« v navodilu za uporabo za druga zdravila, uporabljena v kombinaciji z zdravilom Ribavirin Teva Pharma B.V..
Please refer to the corresponding SmPC of medicinal products used in combination with Ribavirin Teva Pharma B.V. for contraindications specific to these products.
Prosimo, glejte ustrezne povzetke glavnih značilnosti zdravil, uporabljenih v kombinaciji z zdravilom Ribavirin Teva Pharma B.V., za kontraindikacije, specifične za ta zdravila.
Facial palsy, mononeuropathies
paraliza obraznega živca, mononevropatije
The combination of Ribavirin Teva Pharma B.V. with interferon alfa-2b is used to treat adult patients with chronic hepatitis C, who have previously responded to treatment with an alpha interferon alone, but whose condition has recurred.
z interferonom alfa-2b se uporablja za zdravljenje odraslih bolnikov s kroničnim hepatitisom C, ki so se predhodno že odzvali na monoterapijo z enim od interferonov alfa samim, a se jim je bolezen ponovila.
Depression, insomnia, emotional liability
depresija, nespečnost, tesnoba, čustvena labilnost
Ribavirin dose (mg/kg)
HCV genotip odmerek ribavirina (mg/kg)
If you forget to take Ribavirin Teva Pharma B.V.
Če ste pozabili vzeti zdravilo Ribavirin Teva Pharma B.V.
In HCV/HIV co-infected patients receiving cART, the following other side effects have occurred with the combination of ribavirin and peginterferon alfa-2b (not listed above in adults side effects): appetite decreased, back pain, CD4 lymphocytes decreased, defective metabolism of fat, hepatitis, limb pain, oral candidiasis (oral thrush), various laboratory blood values abnormalities.
Pri bolnikih, ki so bili sočasno okuženi z virusoma HCV in HIV in so prejemali terapijo cART, so se med jemanjem kombinacije ribavirina in peginterferona alfa-2b pojavili naslednji drugi neželeni učinki (ki niso našteti zgoraj med neželenimi učinki pri odraslih): - zmanjšan tek, - bolečine v hrbtu, - zmanjšano število limfocitov CD4, - motnje presnove maščob, - hepatitis, - bolečine v udih, - kandidoza u ustih (soor), - nenormalni izvidi različnih laboratorijskih krvnih preiskav.
Due to the risk of lactic acidosis (a build-up of lactic acid in the body) and pancreatitis, the use of ribavirin and didanosine is not recommended and the use of ribavirin and stavudine should be avoided.
uporaba ribavirina z didanozinom ni priporočljiva, uporabi ribavirina in stavudina pa se je treba izogibati.
- have any blood disorder, such as anaemia (low blood count), thalassemia or sickle-cell anaemia
- če ste imeli resne težave s srcem v zadnjih 6 mesecih, - če imate katero od krvnih bolezni, kot so anemija (premajhno število krvnih celic), talasemija ali anemija srpastih celic.
Please refer to the corresponding Summary of Product Characteristics of the antiretroviral medicinal products that are to be taken concurrently with HCV therapy for awareness and management of toxicities specific for each product and the potential for overlapping toxicities with Ribavirin Teva Pharma B.V in combination with other medicinal products.
Prosimo, glejte ustrezne povzetke glavnih značilnosti protiretrovirusnih zdravil, uporabljenih sočasno s terapijo za HCV, da bi se bolj zavedali in bi lahko obvladovali toksične učinke vsakega od teh zdravil ter potencialno prekrivanje njihovih toksičnih učinkov z zdravilom Ribavirin Teva Pharma B.V.
attempted suicide and aggressive behaviour, etc.) - Growth inhibition in children and adolescents that may be irreversible in some patients - Increased thyroid stimulating hormone (TSH) in children and adolescents - Severe ocular disorders - Dental and periodontal disorders.
Med njimi so: - hudi psihiatrični učinki in učinki na osrednje živčevje (kot so depresija, samomorilne misli, poskus samomora in agresivno vedenje itd.); - zastoj rasti pri otrocih in mladostnikih, ki je lahko pri nekaterih bolnikih ireverzibilen; - zvišanje ščitnico stimulirajočega hormona (TSH) pri otrocih in mladostnikih; - hude očesne bolezni; - zobne in obzobne bolezni.
Fungal infection, bacterial infection, pulmonary infection, nasopharyngitis, pharyngitis streptococcal, otitis media, sinusitis, tooth abscess, influenza, oral herpes, herpes simplex, urinary tract infection, vaginitis, gastroenteritis
glivna okužba, bakterijska okužba, okužba pljuč, nazofaringitis, streptokokni faringitis, otitis media, sinuzitis, zobni absces, gripa, herpes v ustih, herpes simpleks, okužba sečil, vaginitis, gastroenteritis